Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Horizon Therapeutics (HZNP) PT Lowered to $162 at Goldman Sachs
May 4, 2022 3:50 PM EDTGoldman Sachs analyst Madhu Kumar lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $162.00 (from $169.00) while maintaining a Buy rating following earnings.
The analyst commented, "Recognizing near-term headwinds for Tepezza related to carryover from omicron delays from 1Q22 into 2Q22,... More
Horizon Therapeutics (HZNP) Tops Q1 EPS by 20c; Maintains Outlook
May 4, 2022 7:10 AM EDTHorizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $1.34, $0.20 better than the analyst estimate of $1.14. Revenue for the quarter came in at $885.2 million versus the consensus estimate of $874.41 million.
GUIDANCE:
Horizon Therapeutics maintains its FY2022 revenue outlook of $3.9-4 billion, versus the... More
